{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"No response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"groups":[{"description":"Initially patients will receive a dose of 500mg (2, 250mg tablets) in the morning and 250mg (1, 250mg tablet) in the afternoon for 2 weeks (cycle 1, days 1-14), then 500mg (2, 250mg tablets) bid for 2 weeks (cycle 1, days 15-28) and finally 750mg (3, 250mg tablets) in the morning and 500mg (2, 250mg tablets) in the afternoon for the remainder of treatment duration (cycle 2, day 1 and onwards). Each 28 days of drug administration will constitute one cycle of therapy.","id":"OG000","title":"PTK787/ZK 222584"}],"paramType":"NUMBER","populationDescription":"Participants were evaluable for response if they completed 3 cycles of treatment. 10 out of 21 participants completed 3 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Day 90","title":"Detectable Paraprotein Level (IgG or IgA)at ≤5 g/dL Who Show a 50% Reduction (Complete Response + Partial Response) in Their Paraprotein After Starting Treatment With the Study Drug","type":"PRIMARY","unitOfMeasure":"participants"}